Targeting The Mutant: NTHI’s NEO100 Data Could Open a New Front in the Fight Against Brain Cancer

DALLAS, Aug. 12, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings (NASDAQ: NTHI) has delivered the kind of clinical update that can change the conversation around a small biotechnology company: its Phase 2a study of intranasal NEO100 in recurrent IDH1-mutant high-grade glioma met its primary endpoint, with six-month progression-free survival of 48.9% versus a pre-specified 20% benchmark for standard of care, producing a reported p-value of 0.0047. The company also reported median overall survival of 26.09 months, with 86.7% of patients alive at six months, 60.9% at 12 months and 54.1% at 24 months. Just as important from a patient perspective, five of the 24 patients remained on treatment, including one patient who had remained progression-free for approximately 19 months and another who had an ongoing partial response beyond 114 days. These are early-stage results from a small, open-label study, not proof that NEO100 works in a broader population, but they are significant enough that NeOnc plans to request a Type B meeting with the U.S. Food and Drug Administration to discuss a registrational development path.